Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

85.70
-0.2900-0.34%
Post-market: 85.750.0490+0.06%19:59 EDT
Volume:6.55M
Turnover:561.69M
Market Cap:214.06B
PE:13.21
High:86.46
Open:85.66
Low:85.24
Close:85.99
52wk High:111.58
52wk Low:73.31
Shares:2.50B
Float Shares:2.49B
Volume Ratio:0.62
T/O Rate:0.26%
Dividend:3.16
Dividend Rate:3.69%
EPS(TTM):6.49
EPS(LYR):6.76
ROE:35.42%
ROA:13.01%
PB:4.37
PE(LYR):12.68

Loading ...

FDA Approval of Subcutaneous Keytruda and Pipeline Updates Might Change The Case For Investing In Merck (MRK)

Simply Wall St.
·
10 hours ago

Citi Resumes Coverage with a Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Yesterday

Merck Price Target Raised to $95.00/Share From $84.00 by Citigroup

Dow Jones
·
Yesterday

Bicara Shares Rise Premarket on FDA Breakthrough Designation

Dow Jones
·
Yesterday

Merck resumed with a Neutral at Citi

TIPRANKS
·
Yesterday

Merck & Co Inc : Citigroup Resumes Coverage With Neutral Rating; Price Target $95

THOMSON REUTERS
·
Yesterday

Immutep receives FDA agreement on optimal dose for efti and advances Phase III lung cancer trial in US

Reuters
·
Yesterday

Pfizer Shares Down 0.8%, Eli Lilly Shares Down 1% in After the Bell Trading

THOMSON REUTERS
·
Oct 11

AstraZeneca US Shares Pare After the Bell Gains, Last up 0.2%

THOMSON REUTERS
·
Oct 11

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments

Benzinga
·
Oct 11

Goldman Sachs Adjusts Merck Price Target to $93 From $94, Maintains Buy Rating

MT Newswires Live
·
Oct 10

Merck & Company: Undervalued with Promising Growth Prospects Despite Near-Term Challenges

TIPRANKS
·
Oct 10

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 10

Immutep announces update for TACTI-004 Phase III trial

TIPRANKS
·
Oct 09

Merck to Present New HIV Treatment and Prevention Data at European AIDS Conference 2025

Reuters
·
Oct 09

Merck announces new clinical trial results and oncology drug data at ESMO 2025

Reuters
·
Oct 09

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at Esmo 2025

THOMSON REUTERS
·
Oct 09

Immutep Says Phase Three Lung Cancer Trial Exceeds Patient Criteria for Futility Analysis

MT Newswires Live
·
Oct 09

Trump Excludes Generics From Big Pharma Tariff Plan

Dow Jones
·
Oct 09

Key US vaccine panel meeting delayed, agenda unclear

Reuters
·
Oct 09